Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence
Highlights
- Once-weekly semaglutide 2.4 mg induces robust and clinically meaningful bodyweight reduction in Chinese adults with overweight or obesity, including those with type 2 diabetes.
- The STEP 12 trial demonstrated a weight loss of approximately 12.1% over 44 weeks, significantly outperforming placebo with strong statistical confidence.
- Gastrointestinal adverse events are common but consistent with the known safety profile of semaglutide and are generally manageable.
- Additional studies including STEP 7 and REDEFINE 5 confirm the efficacy of semaglutide alone or in combination therapies in East Asian populations, supporting its broader clinical adoption.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.